Canterbury DHB
Buprenorphine (Temgesic™) injection is inferior to Morphine and is NOT recommended. Low dose transdermal buprenorphine (NorspanTM) has recently been licensed in New Zealand but is not funded. It is unlikely that it will be used commonly in Palliative Care but its efficacy and appropriateness are yet to be established.
Hydromorphone is not available in New Zealand.
Pethidine
Note: The risk of pethidine toxicity is increased with high doses and/or long term use and SHOULD NOT be used in chronic cancer-related pain.
Regular oral doses above 300 mg daily can be dangerous.
75 mg IM Pethidine @ 10 mg subcut Morphine.
Have you read the |
|
Topic Code: 4431